Compare HOV & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | MRVI |
|---|---|---|
| Founded | 1959 | 2014 |
| Country | United States | United States |
| Employees | 1891 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.8M | 559.0M |
| IPO Year | N/A | 2020 |
| Metric | HOV | MRVI |
|---|---|---|
| Price | $122.02 | $4.97 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $97.00 | $4.13 |
| AVG Volume (30 Days) | 95.7K | ★ 2.7M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | $5.96 | $7.87 |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $90.79 | $1.99 |
| 52 Week High | $162.06 | $5.30 |
| Indicator | HOV | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 62.10 |
| Support Level | $117.28 | $3.27 |
| Resistance Level | $127.22 | $5.00 |
| Average True Range (ATR) | 5.58 | 0.25 |
| MACD | 1.36 | 0.00 |
| Stochastic Oscillator | 79.68 | 64.80 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.